KeyWEn.com  
 
 
 
Adverse Events       Article     History   Tree Map
  Encyclopedia of Keywords > Humans > Health > Diseases > Patients > Adverse Events   Michael Charnine

Keywords and Sections
ADVERSE REACTIONS
PHARMACOKINETICS
PEDIATRIC PATIENTS
FREQUENT ADVERSE EVENTS
FREQUENT
TRIALS
CLINICAL TRIALS
CONTROL GROUPS
POLICOSANOL
HEALTHY VOLUNTEERS
SEPSIS
NINE PATIENTS
BLEEDING COMPLICATIONS
ZONISAMIDE
DROPOUTS
CLINICAL IMPROVEMENT
TWELVE PATIENTS
AMITRIPTYLINE
OVERALL RATE
PLACEBO TREATMENT
ECULIZUMAB
SEVEN PATIENTS
FOUR SUBJECTS
ALBENDAZOLE
LABORATORY TESTS
FEWER PATIENTS
STUDY DRUG
SAFETY ANALYSIS
SIMILAR EFFICACY
ABDOMINAL
SIMILAR RATES
SUMATRIPTAN
RIZATRIPTAN
TREATMENT DISCONTINUATION
STUDY TREATMENT
TEGASEROD
SAFETY PARAMETERS
LABORATORY PARAMETERS
STUDIES
GREATER REDUCTION
PATIENTS RECEIVING PLACEBO
PRURITUS
INJECTION SITE REACTIONS
META-ANALYSIS
DOSE-RELATED
FOUR PATIENTS
Review of Short Phrases and Links

    This Review contains major "Adverse Events"- related terms, short phrases and links grouped together in the form of Encyclopedia article.

Definitions

  1. Adverse events were typically mild to moderate and occurred with similar frequency and severity between the nitazoxanide and placebo groups.
  2. Adverse events were similar in all groups, with transient diarrhoea being the only adverse event seen more frequently with tegaserod than placebo. (Web site)
  3. Adverse events were similar between the treatment groups, the most common being headache and abdominal pain. (Web site)
  4. Adverse events were comparable between groups; 16.1% of rituximab and 13.6% of placebo patients reported serious events.
  5. Adverse events were common given the participants' advanced stage of disease, but frequency was similar in the rifaximin and placebo groups (both 80%).

Adverse Reactions

  1. Patients should be monitored for potential adverse events (see ADVERSE REACTIONS).

Pharmacokinetics

  1. The purpose of this study was to determine the pharmacokinetics of cefepime in this population to optimize dosing and minimize potential adverse events. (Web site)
  2. Search terms included, but were not limited to, entecavir, BMS-200475, hepatitis B, pharmacology, pharmacokinetics, adverse events, and therapeutic use.
  3. Blood and urine samples were obtained pre- and postinfusion for analysis of safety and pharmacokinetics, and data on adverse events were gathered. (Web site)

Pediatric Patients

  1. Pediatric CRF Patients: In pediatric patients with CRF on dialysis, the pattern of most adverse events was similar to that found in adults. (Web site)
  2. The adverse events most commonly associated with withdrawal in pediatric patients were emotional lability (1.6%), hostility (1.3%), and hyperkinesia (1.1%). (Web site)
  3. Benzyl alcohol, a component of this drug product, has been associated with serious adverse events and death, particularly in pediatric patients. (Web site)

Frequent Adverse Events

  1. The most frequent adverse events seen in the placebo-controlled clinical trials in adults with rheumatoid arthritis (HUMIRA vs. (Web site)
  2. The most frequent adverse events included tremor, hyperglycemia, hypertension, and infection, but none were severe.
  3. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. (Web site)

Frequent

  1. The most frequent adverse events were nausea, vomiting, and tremor.
  2. Headache and dizziness were the two most frequent adverse events and were more than twice as frequent in the BiDil group. (Web site)
  3. The most frequent adverse events were drowsiness, ataxia, loss of appetite or gastrointestinal symptoms and slowing of mental activity. (Web site)

Trials

  1. In general, most patients who experienced adverse events during the first eight weeks of these trials no longer experienced them by their last visit. (Web site)

Clinical Trials

  1. The following adverse events were reported, regardless of causality assessment in patients treated with atorvastatin in clinical trials. (Web site)
  2. The incidence of adverse events in controlled clinical trials was not affected by gender or age of the patients.
  3. This section reports additional, less frequent adverse events which occurred among the patients taking clozapine in clinical trials. (Web site)

Control Groups

  1. Adverse events were generally similar across treatment and control groups. (Web site)
  2. The incidence of serious adverse events and death were balanced between the vaccine and control groups.

Policosanol

  1. CONCLUSIONS: Subjects in the group treated with policosanol did not have serious adverse events during the 24-week study.
  2. Policosanol was better tolerated than atorvastatin as revealed by patient withdrawal analysis and overall frequency of adverse events. (Web site)
  3. Policosanol was well tolerated, and no significant adverse events were noted. (Web site)

Healthy Volunteers

  1. The placebo effect in healthy volunteers: Influence of experimental conditions on the adverse events profile during phase I studies.

Sepsis

  1. In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis. (Web site)
  2. The most common serious adverse events were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea and thrombocytopenia. (Web site)
  3. The following adverse events reported in patients receiving ganciclovir may be potentially fatal: pancreatitis, sepsis, and multiple organ failure.

Nine Patients

  1. Nine patients reported 10 adverse events, none related to treatment. (Web site)

Bleeding Complications

  1. Bleeding complications, stroke or intracerebral haemorrhage are potential adverse events for both treatments. (Web site)

Zonisamide

  1. Zonisamide was withdrawn in two patients due to adverse events. (Web site)
  2. Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with zonisamide.
  3. Use of zonisamide was frequently associated with central nervous system-related adverse events.

Dropouts

  1. The numbers of dropouts due to adverse events were equal in valacyclovir (2) and placebo (2) groups.

Clinical Improvement

  1. Clinical improvement of HA and adverse events are 2 outcome measures frequently used in the included trials for symptomatic treatment of migraine attacks. (Web site)
  2. Patients were observed for clinical improvement, drug side-effects and any serious or unexpected adverse events.

Twelve Patients

  1. Twelve patients withdrew from the study due to adverse events, of which four were judged to be due to study medication. (Web site)
  2. Twelve patients (13%) discontinued treatment owing to adverse events.

Amitriptyline

  1. Adverse events were experienced by 17 patients taking amitriptyline and 18 patients taking gabapentin.

Overall Rate

  1. Moreover, the overall rate of adverse events was similar in the amitriptyline and gabapentin groups. (Web site)
  2. The overall rate of adverse events due to acupuncture was 8.75%. (Web site)

Placebo Treatment

  1. Adverse events significantly more common during modafinil compared with placebo treatment were nausea (9% vs. (Web site)

Eculizumab

  1. The most frequent adverse events with eculizumab were headache, nasopharyngitis and back pain. (Web site)

Seven Patients

  1. Seven patients in the oxycodone CR group (n=22) and 1 in the placebo group (n=11) withdrew because of adverse events. (Web site)
  2. Eleven episodes (18.0%) of adverse events (possibly, probably, definitely related) were reported in seven patients (11.5%).

Four Subjects

  1. In O'Mahony's study [ 27] (80 participants), four subjects reported adverse events during the study.
  2. Four subjects treated with divalproex ER and three treated with placebo discontinued because of adverse events.

Albendazole

  1. Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed. (Web site)

Laboratory Tests

  1. Safety was assessed by recording adverse events, laboratory tests, and vital signs at each visit during the study.

Fewer Patients

  1. Overall, fewer patients with adverse events were observed in the OLA group (p = 0.04).

Study Drug

  1. The study drug was discontinued due to adverse events in 2 patients (2.6%) of Group I, and in 3 patients (3.8%) of Group II (p=0.523).
  2. Two serious adverse events (SAEs) were reported on treatment - neither were considered to be related to the study drug. (Web site)
  3. Table 2 lists adverse events that occurred in placebo-controlled clinical trials in patients who took at least 1 dose of study drug.

Safety Analysis

  1. Safety analysis was based on the incidence of adverse events.

Similar Efficacy

  1. Results further showed Prexige and ibuprofen had similar efficacy as well as a comparable incidence of adverse events.

Abdominal

  1. Adverse events more common in patients given BG00012 than in those given placebo included abdominal pain, flushing, and hot flush.
  2. The most frequent adverse events thought to be related to atorvastatin were constipation, flatulence, dyspepsia, and abdominal pain.
  3. Other common adverse events in the three eltrombopag groups were dry mouth, abdominal pain, and nausea. (Web site)

Similar Rates

  1. There were similar rates of adverse events in the two treatment groups.
  2. Dextofisopam and placebo had similar rates and types of adverse events, with more events of worsening abdominal pain with dextofisopam (12% vs.

Sumatriptan

  1. The use of rescue medication was significantly more for placebo, whereas the number of adverse events was significantly more for sumatriptan. (Web site)

Rizatriptan

  1. Adverse events during rizatriptan were mild and transient; similar events occurred during placebo, with a somewhat reduced incidence. (Web site)

Treatment Discontinuation

  1. The rates of treatment discontinuation because of adverse events were 38.6% and 13.6% in the amitriptyline and pregabalin groups, respectively. (Web site)
  2. No serious adverse events resulted in treatment discontinuation.

Study Treatment

  1. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. (Web site)
  2. Adverse events occurring during and up to 1 day after the end of study treatment are shown in Table 2. (Web site)

Tegaserod

  1. There were no consistent differences in adverse events between patients previously exposed to tegaserod and those treated de novo.
  2. The most common adverse events, headache and abdominal pain, were more frequent with placebo than with tegaserod.

Safety Parameters

  1. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. (Web site)

Laboratory Parameters

  1. Safety parameters included adverse events, laboratory parameters, vital signs and physical examination. (Web site)
  2. Safety variables were adrenal function, monitoring of adverse events, vital signs, and laboratory parameters.

Studies

  1. The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.
  2. Even so, few studies have found evidence of an increased risk of adverse events among diabetic divers.
  3. Adverse events observed in pediatric patients in controlled studies were comparable to those observed in adult patients.

Greater Reduction

  1. Outcomes were: (1) 50% or greater reduction in total seizure frequency; (2) treatment withdrawal; (3) adverse events. (Web site)

Patients Receiving Placebo

  1. Adverse events were reported in 52% (n=263) of patients receiving DETROL LA and in 49% (n=247) of patients receiving placebo. (Web site)
  2. Zonegran was generally well-tolerated at all doses, with adverse events occurring in a similar proportion to patients receiving placebo. (Web site)

Pruritus

  1. There was no difference in adverse events between the lidocaine and placebo groups, and the most commonly reported events were rash and pruritus. (Web site)
  2. We did not find significant effects of methotrexate on pruritus, fatigue, liver complications, liver biochemistry, liver histology, or adverse events. (Web site)

Injection Site Reactions

  1. Consistent with previous studies evaluating mipomersen, the most commonly observed adverse events were injection site reactions and flu-like symptoms. (Web site)

Meta-Analysis

  1. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. (Web site)
  2. Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN. (Web site)
  3. Figure 4: Meta-analysis of serious adverse events and death in selected studies of prophylactic vaccination against HPV-related infection and disease.

Dose-Related

  1. Dose-related adverse events in patients on BG00012 were headache, fatigue, and feeling hot.
  2. Adverse events occurred with similar incidence in all treatment groups, with no dose-related increases in any event.
  3. The overall frequency of adverse events was not dose-related. (Web site)

Four Patients

  1. Four patients discontinued treatment due to adverse events.

Categories

  1. Humans > Health > Diseases > Patients
  2. Discontinuation
  3. Society > Humans > Medicine > Placebo
  4. Evaluation > Analysis > Tests > Treatment Groups
  5. Incidence

Related Keywords

    * Adverse Effects * Adverse Events Associated * Aes * Associated * Asthenia * Causal Relationship * Clinical Studies * Common * Common Adverse Events * Discontinuation * Discontinuations * Dizziness * Dose Reduction * Efficacy * Extrapyramidal Symptoms * Frequency * Gastrointestinal * Groups * Headache * Incidence * Incidences * Injection Site * Investigator * Investigators * Laboratory Values * Leukine * Mild * Moderate * Nausea * Nitazoxanide * Overall Incidence * Own Choosing * Patients * Patient Population * Placebo * Placebo-Treated Patients * Placebo Group * Placebo Groups * Placebo Patients * Pravastatin * Related * Risk * Safety * Safety Profile * Secondary Outcomes * Serious Adverse Events * Severity * Side Effects * Significant Difference * Significant Differences * Similar * Similar Frequency * Somnolence * Study * Therapy * Three Patients * Three Treatment Groups * Tolerability * Treatment * Treatment Arms * Treatment Group * Treatment Groups * Treatment Studies * Vital Signs * Vomiting * Withdrawal * Withdrawals
  1. Books about "Adverse Events" in Amazon.com

Book: Keywen Category Structure


  Short phrases about "Adverse Events"
  Originally created: April 04, 2011.
  Links checked: April 06, 2013.
  Please send us comments and questions by this Online Form
  Please click on Move Up to move good phrases up.
0.0175 sec. a=1..